Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.

Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J.

J Oncol Pract. 2019 Sep;15(9):e825-e834. doi: 10.1200/JOP.18.00703. Epub 2019 Aug 6.

PMID:
31386608
2.

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

Suresh K, Naidoo J, Zhong Q, Xiong Y, Mammen J, de Flores MV, Cappelli L, Balaji A, Palmer T, Forde PM, Anagnostou V, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Lin CT, Feller-Kopman D, Lerner AD, Lee H, Shafiq M, Yarmus L, Lipson EJ, Soloski M, Brahmer JR, Danoff SK, D'Alessio F.

J Clin Invest. 2019 Jul 16;130. pii: 128654. doi: 10.1172/JCI128654.

3.

A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer.

Parikh AB, Marrone KA, Becker DJ, Brahmer JR, Ettinger DS, Levy BP.

Cancer Treat Res Commun. 2019;20:100150. doi: 10.1016/j.ctarc.2019.100150. Epub 2019 May 10.

PMID:
31102920
4.

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.

Voong KR, Hazell SZ, Fu W, Hu C, Lin CT, Ding K, Suresh K, Hayman J, Hales RK, Alfaifi S, Marrone KA, Levy B, Hann CL, Ettinger DS, Feliciano JL, Peterson V, Kelly RJ, Brahmer JR, Forde PM, Naidoo J.

Clin Lung Cancer. 2019 Jul;20(4):e470-e479. doi: 10.1016/j.cllc.2019.02.018. Epub 2019 Mar 28.

PMID:
31031204
5.

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Mar 6;7(1):63. doi: 10.1186/s40425-019-0547-7.

6.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Feb 11;7(1):40. doi: 10.1186/s40425-018-0492-x. Erratum in: J Immunother Cancer. 2019 Mar 6;7(1):63.

7.

Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.

Phallen J, Leal A, Woodward BD, Forde PM, Naidoo J, Marrone KA, Brahmer JR, Fiksel J, Medina JE, Cristiano S, Palsgrove DN, Gocke CD, Bruhm DC, Keshavarzian P, Adleff V, Weihe E, Anagnostou V, Scharpf RB, Velculescu VE, Husain H.

Cancer Res. 2019 Mar 15;79(6):1204-1213. doi: 10.1158/0008-5472.CAN-18-1082. Epub 2018 Dec 20.

8.

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.

Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, Hales RK, D'Alessio F, Danoff SK, Naidoo J.

J Thorac Oncol. 2019 Mar;14(3):494-502. doi: 10.1016/j.jtho.2018.11.016. Epub 2018 Nov 30.

PMID:
30503891
9.

Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.

Boozalis E, Kwatra SG, Marrone KA.

JAMA Oncol. 2019 Feb 1;5(2):261-262. doi: 10.1001/jamaoncol.2018.4485. No abstract available.

PMID:
30286225
10.

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.

Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, D'Alessio F, Hales RK, Lin CT, Psoter KJ, Danoff SK, Naidoo J.

J Thorac Oncol. 2018 Dec;13(12):1930-1939. doi: 10.1016/j.jtho.2018.08.2035. Epub 2018 Sep 26.

PMID:
30267842
11.

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity.

Danilova L, Anagnostou V, Caushi JX, Sidhom JW, Guo H, Chan HY, Suri P, Tam A, Zhang J, Asmar ME, Marrone KA, Naidoo J, Brahmer JR, Forde PM, Baras AS, Cope L, Velculescu VE, Pardoll DM, Housseau F, Smith KN.

Cancer Immunol Res. 2018 Aug;6(8):888-899. doi: 10.1158/2326-6066.CIR-18-0129. Epub 2018 Jun 12.

12.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM.

N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

13.

Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.

Yeh J, Marrone KA, Forde PM.

J Thorac Dis. 2018 Feb;10(Suppl 3):S451-S459. doi: 10.21037/jtd.2018.01.109. Review.

14.

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.

Marrone KA, Zhou X, Forde PM, Purtell M, Brahmer JR, Hann CL, Kelly RJ, Coleman B, Gabrielson E, Rosner GL, Ettinger DS.

Oncologist. 2018 Jul;23(7):859-865. doi: 10.1634/theoncologist.2017-0465. Epub 2018 Feb 27.

15.

Cancer Immunotherapy in Older Patients.

Marrone KA, Forde PM.

Cancer J. 2017 Jul/Aug;23(4):219-222. doi: 10.1097/PPO.0000000000000268. Review.

PMID:
28731944
16.

Resolution of Carbapenemase-Producing Klebsiella pneumoniae Outbreak in a Tertiary Cancer Center; the Role of Active Surveillance.

Rock C, Curless MS, Cantara M, Mehta S, Marrone KA, Carroll KC, Simner P, Maragakis LL.

Infect Control Hosp Epidemiol. 2017 Sep;38(9):1117-1119. doi: 10.1017/ice.2017.136. Epub 2017 Jul 11. No abstract available.

PMID:
28693656
17.

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.

Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO 3rd, Brahmer JR.

Oncologist. 2017 Jun;22(6):627-630. doi: 10.1634/theoncologist.2016-0390. Epub 2017 Jun 2. No abstract available.

18.

Immunotherapy for Lung Cancer: No Longer an Abstract Concept.

Marrone KA, Naidoo J, Brahmer JR.

Semin Respir Crit Care Med. 2016 Oct;37(5):771-782. Epub 2016 Oct 12. Review.

PMID:
27732998
19.

Using Immune Checkpoint Inhibitors in Lung Cancer.

Marrone KA, Brahmer JR.

Oncology (Williston Park). 2016 Aug;30(8):713-21. Review.

20.

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.

Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, Ott PA, Yamashita M, Leaf DE.

Kidney Int. 2016 Sep;90(3):638-47. doi: 10.1016/j.kint.2016.04.008. Epub 2016 Jun 7.

21.

Immune-Related Adverse Events From Immune Checkpoint Inhibitors.

Marrone KA, Ying W, Naidoo J.

Clin Pharmacol Ther. 2016 Sep;100(3):242-51. doi: 10.1002/cpt.394. Epub 2016 Jul 29. Review.

PMID:
27170616
22.

Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.

Marrone KA, Brahmer JR.

Cancer J. 2016 Mar-Apr;22(2):81-91. doi: 10.1097/PPO.0000000000000178. Review.

PMID:
27111902
23.

Nivolumab for refractory metastatic squamous non-small-cell lung cancer: fulfilling an unmet need.

Marrone KA, Forde PM.

Transl Lung Cancer Res. 2015 Dec;4(6):801-3. doi: 10.3978/j.issn.2218-6751.2015.05.04. No abstract available.

Supplemental Content

Loading ...
Support Center